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Variation between inbred mice of susceptibility to experimental Trypanosoma cruzi infection has frequently been described,
but the immunogenetic background is poorly understood. The outcross of the susceptible parental mouse strains C57BL/6 (B6)
and DBA/2 (D2), B6D2F1 (F1) mice, is highly resistant to this parasite. In the present study we show by quantitative PCR that
the increase of tissue parasitism during the early phase of infection is comparable up to day 11 between susceptible B6 and
resistant F1 mice. A reduction of splenic parasite burdens occurs thereafter in both strains but is comparatively retarded in
susceptible mice. Splenic microarchitecture is progressively disrupted with loss of follicles and B lymphocytes in B6 mice, but
not in F1 mice. By genotyping of additional backcross offspring we corroborate our earlier findings that susceptibility maps to
three loci on Chromosomes 5, 13 and 17. Analysis of gene expression of spleen cells from infected B6 and F1 mice with
microarrays identifies about 0.3% of transcripts that are differentially expressed. Assuming that differential susceptibility is
mediated by altered gene expression, we propose that the following differentially expressed transcripts from these loci are
strong candidates for the observed phenotypic variation: H2-Ea, H2-D1, Ng23, Msh5 and Tubb5 from Chromosome 17; and
Cxcl11, Bmp2k and Spp1 from Chromosome 5. Our results indicate that innate mechanisms are not of primary relevance to
resistance of F1 mice to T. cruzi infection, and that differential susceptibility to experimental infection with this protozoan
pathogen is not paralleled by extensive variation of the transcriptome.
Citation: Graefe SEB, Streichert T, Budde BS, Nu ¨rnberg P, Steeg C, et al (2006) Genes from Chagas Susceptibility Loci That Are Differentially Expressed
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INTRODUCTION
Chagas’ disease severely affects a considerable number of persons
on the American continent, but in the majority of infected, it takes
an ‘indeterminate’ course over a long period of time [1]. Genetic
factors determining the course and outcome of the infection are
thought to be of major influence on the severity of the disease [2–
6], but the precise background has not been elucidated. Variablity
of parasite strains contributes to the complex host-pathogen
interaction [3]. As in human disease, the experimental infection
has an early parasitaemic phase, which is followed by chronic
infection that may or may not lead to the symptoms characteristic
of the disease. Some controversy has prevailed over the question
whether the severity of the acute phase of the infection and the
degree of parasitaemia and/or tissue parasitism correlated with the
severity of the chronic complications of Chagas’ disease. Recently,
it has increasingly been appreciated that the persistence of
parasites, rather than the occurence of autoreactive antibodies or
cells, determines the degree of tissue destruction [7–11]. It was
shown that an early phase with high parasitic loads resulted in
a late phase with more prominent repercussions on the integrity of
affected tissue, with more intense inflammatory infiltrates, more
tissue destruction and greater loss of physiological function
[12,13].
The course of experimental T. cruzi infection in inbred strains of
mice varies considerably depending on the mouse strain, the route
of infection, the parasite strain, and the clone of a given parasite
strain [14–16]. Other than with Leishmania, no consistent picture
has evolved that would relate a certain type of immunologic
reactivity with protection from severe disease. It has been noted
that certain H2 haplotypes confer a degree of resistance [17–19].
The requirement for pro-inflammatory cytokines such as IL-12,
IFN-c, and TNF-a, as well as for MHC-class I and II molecules,
CD4+ and CD8+ T lymphocytes and the synthesis of antigen-
specific antibodies, for protective immunity has repeatedly been
demonstrated [20–25]. Generally, a higher degree of expression of
anti-inflammatory cytokines such as IL-4, IL-10 and TGF-b was
correlated with increased severity of infection, but some conflicting
results have been published (e.g., [26,27]).
In contrast to the parental strains C57BL/6 (B6) and DBA/2
(D2), B6D2F1 (F1) hybrid mice display a considerable degree of
resistance to experimental infection in terms of parasitaemia levels
and rates of mortality, but precise mechanisms that explained the
unusual phenotype of this strain have not been identified. By
comparison with susceptible B6 mice, resistance in F1 mice was
related to decreased expression of IL-10 and TGF-b in the early
phase [21,28]. However, the isolated analysis of cytokine
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PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e57responses, and the correlation of cytokine expression or regulatory
molecules with outcome, bear the danger of focussing on
secondary effects or on counter-regulative reactivity, rather than
identifying the initial cause for differential outcomes. In the
present work, we therefore investigated at which stage of
experimental infection tissue parasite loads dissociated between
susceptible B6 and resistant F1 mice in order to identify the time
point at which the immune responses diverge. We then analysed
genomewide expression differences at this time point in the spleen,
identified transcriptional correlates for differential outcomes and
matched the genomic localisation of these genes with mapped
susceptibility loci.
RESULTS
Experimental T. cruzi infection in susceptible B6 and
in resistant F1 mice
Infection of B6 mice with 10
4 trypomastigotes of the T. cruzi
tulahuen strain caused an acute illness that was usually lethal.
Mice succumbed between days 20 and 30 after infection (fig. 1 A).
Shortly before death, parasitaemia increased to well over 10
6/ml
(fig. 1 B). In F1 mice, there was a transient para–sitaemic phase
around day 13, but parasitaemia did not exceed 10
6/ml, and all
mice invariably survived experimental infection under these
conditions (fig 1 A, B). Tissue parasite loads were quantified by
real time PCR in various organs during the early phase of the
infection (until day 17, fig. 1 C–F). Interestingly, the degree of
tissue parasitism was not significantly different in the first 11 days
of infection between mouse strains. Resistant F1 mice actually
displayed slightly higher parasite loads in all tested tissues up to
this stage. After day 11, tissue parasite load declined in resistant
mice, while it further increased in spleens of susceptible B6 mice.
Thereafter, parasitism decreased in susceptible mice, too, in all
tested organs. The rate of parasite clearance in the spleen was
lower than in F1 mice. These results indicate that innate resistance
is not compromised, if not more effective, in B6 mice. They also
indicate that acquired immune responses develop in B6 mice with
a delay and appear to be less efficient in containing tissue
parasitism, especially in the spleen and liver.
Splenic architecture was severely disrupted, and
cellular composition was altered, in susceptible mice
infected with T. cruzi
After day 10 of infection, there was a striking difference of parasite
loads in the spleen between the mouse strains. Splenomegaly was
present in all infected mice to the same extent (total spleen cell
numbers increased to about 1–2610
8 in either strain) and pointed
to a strong involvement of the spleen in the immune response to T.
cruzi. We thus assessed by histologic analysis whether splenic
architecture was modified, and by flow cytometry whether there
were quantitative differences in splenic cellular composition
between B6 and F1 mice.
Histologically, the appearance of red and white pulp, the
numbers and size of primary follicles, and the distribution of
periarteriolar lymphatic sheaths (PALS) was not obviously
different in naive mice, and the cellular localisation of cells
expressing CD4, CD8, CD19 and CD11b was indistinguishable
(fig. 2 A, B and data not shown). By day 13 of an experimental
infection with T. cruzi, splenic microarchitecture was observed to
be disrupted in B6 mice but not in F1 mice (fig. 2 C, D). The
disruption was even more severe on day 23 (not shown). In F1
mice, abundant cells with intracellular apoptotic bodies, re-
sembling tingible body macrophages, were seen in secondary
follicles (fig. 2 D, inset), but these were not observed in B6 mice.
Periarteriolar sheaths (PALS) were reduced by numbers and
Figure 1. Experimental T. cruzi infection in susceptible B6 and in resistant F1 mice. Mice were infected with 10
4 T. cruzi trypomastigotes into the
peritoneum. Survival was monitored up to day 60. Parasitaemia was determined in a Neubauer chamber. Tissue parasite loads in spleen, liver, heart
and skeletal muscle were determined by real time PCR and are expressed as arbitrary log units of T. cruzi DNA relative to quantity of murine b-actin
DNA.
doi:10.1371/journal.pone.0000057.g001
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the spleen (fig. 2 E). In F1 mice, some prominent PALS consisting
of CD4+ T cells were detectable (fig. 2 F). Follicles with CD19+ B
lymphocytes were also reduced in size and numbers in the spleen
of infected B6 mice (fig. 2 G). Contrarily, in resistant F1 mice,
prominent B cell follicles were present adjacent to PALS (fig. 2 H).
CD8 T cells did generally not co-localise to PALS in susceptible
mice, but were located in the remains of the red and white pulp
(fig. 2 I). In F1 mice, CD8+ cells formed small clusters in the red
pulp and co-localised with PALS (fig. 2 K). In summary, the main
difference in splenic microarchitecture between mouse strains was
the obvious loss of compartmentalised organisation of lyphocytes
in susceptible but not in resistant mice.
The proliferation of T. cruzi within macrophages has been
shown to be enhanced in the presence of apoptotic T cells due to
a downregulatory effect of apoptotic bodies on trypanocidal
effector functions of infected macrophages [29]. We therefore
determined the quantitiy and distribution of apoptotic cells in the
spleens of infected mice. In spleens from B6 mice, abundant
apoptotic cells (identified by the TUNEL reaction) were found
throughout the spleen, and they were frequently located sub-
capsularly and in the remaining T cell areas, (fig. 2 L). By contrast,
apoptotic cell numbers were lower, and they were mainly found in
the centre of follicles, in the spleen of F1 mice (fig. 2 M).
The splenic cellular composition in infected mice was analysed
cytometrically with explanted spleen cells to verify the histologic
alterations. In naive mice, relative numbers of splenic CD4+ T
cells, CD8+ T cells, CD19+ B cells and CD11b+ macrophages did
not differ between mice (fig. 3 A). However, cell fractions were
notably different later during infection. On day 24 of infection,
prior to the detrimental outcome in B6 mice, CD19+ B
lymphocytes were decreased at around 30% of cells (fig 3 B) in
susceptible B6 mice. Interestingly, in infected F1 mice, the fraction
of B cells was similar to that of control mice (about 60%, fig. 3 B).
The fraction of CD4+ lymphocytes was 10–15% in both strains
(not shown). Splenic CD8+ T cells increased to around 20–25% of
cells in B6 mice, and to about 15% in F1 mice (not shown).
Strikingly, in B6 mice, relative numbers of CD11b+ macrophages
drastically increased more than tenfold, from about 3% in naive
mice to 30–50% in infected mice, but in F1 mice, the increase
was less pronounced to about 10–20% of spleen cells (fig. 3 B). In
summary, a strong bias towards macrophages, and a slight
bias towards CD8+ T cells, at the expense of B lymphocytes, was
found in the spleen of infected B6 mice, but not in resistant F1
mice.
In naive mice, numbers of apoptotic cells were low at around
1% (determined cytometrically by staining with Annexin V) and
did not differ between the two strains (not shown). In infected
mice, however, there was a strong increase of Annexin V (AxV)
positive cells in B6 mice (fig 3 B). The relative number of cells
expressing AxV was 10–20%, with half of these also staining with
propidium iodide (PI), indicating that these cells had lost integrity
of the cell membrane. In infected F1 mice, AxV positive cells
increased to about 2–5%. The proportion of cells stained by PI
only was about 10% in either strain, indicating that preparation of
samples had equal effects on staining of cells in causing some
degree of cell death. In summary, susceptible mice displayed
a considerably higher rate of apoptosis in the spleen, possibly
accounting for the reduced numbers of B cells.
Significant linkage of susceptibility to loci on
Chromosomes 5 and 17, and suggestive linkage on
Chromosome 13
We previously mapped genomic loci as being either suggestively
(Chromosome 5) or significantly (Chromosome 17) linked to
susceptibility to lethal experimental T. cruzi infection, respectively
[30]. The score of a further genomic region on Chromosome 13
did not attain the threshold level for genome-wide linkage but
appeared to be involved, too. In an extension study, designed to
confirm linkage of a locus previously reported as suggestively
linked [31], we phenotyped further male B6xF1 backcross mice,
and another 22 mice died during the early phase (up to day 50) of
infection. The candidate regions were genotyped with micro-
satellite markers in these mice, and the resulting data replicated
that susceptibility mapped to the reported locus on Chromosome
17, and further substantiated the linkage evidence for the loci on
Chromosomes 5 and 13 by raising it to the level of significant and
suggestive linkage, respectively (fig. 4).
Even though the genes conferring susceptibility are thus
mapped, the respective genetic regions are large and the number
Figure 2. Splenic architecture and cellular composition in susceptible
B6 and in resistant F1 mice. Spleens from B6 mice (left panel) and from
F1 mice (right panel) were either fixed in paraformaldehyde, embedded
in paraffin, and subsequently stained with hematoxylin and eosin (A–D),
or they were shock frozen in liquid nitrogen and analysed by
immunohistochemistry (C–M). Sections are from naive mice (A, B) or
from T. cruzi- infected mice (C–M) at the indicated day of infection.
Cryosections were stained for CD4 (E, F), CD19 (G, H), CD8 (I, K), or by
the TUNEL reaction (L, M). Micrographs A–K at original magnification
1006, micrographs L, M and insert in D at 4006; inset in D shows centre
of a secondary follice.
doi:10.1371/journal.pone.0000057.g002
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genes themselves are not straightforward. However, it is generally
accepted that quantitative differences of transcription determine
the outcome of an infection with a complex immunogenetic
background. The kinetics of tissue parasite loads during early
experimental T. cruzi infection in the two differentially susceptible
mouse strains indicate that after about day 10, the implementation
of effector immune responses was impaired but not abrogated in
susceptible B6 mice. The described differences in parasite
proliferation, splenic architecture and splenic cellular composition
progressively developed after this time point. Since the spleen
appeared to be fundamentally involved in the differential
immunity to the parasite, we therefore analysed genome wide
expression in explanted spleen cells from either mouse strain in
order to identify genes that were differentially transcribed and that
mapped to the susceptibility loci. We chose to analyse expression
Figure 3. Cellular composition of the spleen from naive and T. cruzi- infected mice. Single spleen cell suspensions from naive mice (A) and from
mice infected on day 24 with T. cruzi (B) were analysed by flow cytometry. Cells were stained for both CD4 and CD8, for CD19, for CD11b, or with
propidium iodide (PI) and Annexin V (AxV). Numbers indicate percentage of cells expressing the respective marker. B6, C57BL/6 mice; F1, B6D2F1
mice.
doi:10.1371/journal.pone.0000057.g003
Figure 4. Murine T. cruzi susceptibility loci map to Chromosomes 5, 13, and 17. Nine microsatellite markers from the three candidate genomic
regions previously identified as suceptibility loci [30] were typed in an additional 22 T. cruzi- susceptible B6xF1 backcross mice (see table 3 for
respective markers). Single-point (dashed line) and multi-point (solid line) calculations of x
2 are shown for all 68 susceptible backcross mice including
the 46 from the original study. Dotted lines at x
2=16.56 and x
2=8.74 indicate thresholds for suggestive and significant linkage, respectively.
doi:10.1371/journal.pone.0000057.g004
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a divergent course. At this stage, the cellular composition of the
spleen was marginally different between mouse strains in that there
were more CD8+ cells (7% vs. 4%) in B6 mice, but fewer CD19+
cells,(10%vs.18%)inB6mice,whiletheproportionofCD4+and of
CD11b+ cells was comparable (12% and 17–20%, respectively).
Differential gene expression in the spleens of
susceptible B6 and from resistant F1 mice on day 11
of T. cruzi infection
We used mouse expression arrays containing 22690 transcripts
and obtained three biologically independent specimen pairs. Data
were normalised using target value scaling (target value: 100).
Expression was considered significantly different when it showed
a concordant regulation in at least 6 of 9 crosswise comparisons
and a signal log ratio of 0.8 (fold change of 1.6) or more. Applying
these criteria, we found that 28 transcripts were upregulated and
42 transcripts were downregulated in B6 mice, compared to F1
mice (tables 1 and 2). A second, biologically independent experi-
ment was performed in which we analysed the transcription profile
of pooled spleen cells from three infected animals of each strain to
confirm transcriptional differences. Applying the same statistical
algorithms and criteria, we could verify the differential expression
of 14 transcripts with increased expression and of 35 transcripts
with decreased expression (highlighted by bold gene titles, tables 1
and 2).
Over all, only about 0.3% of transcripts present on the
microarray were found to be differentially expressed between the
two mouse strains. Among these were a number of genes that are
involved in immune responses or inflammatory processes, such as:
the T cell receptor (TCR) Vb 13; the TCR gamma chain;
osteopontin (Opn,o rSpp1, secreted phosphoprotein 1); comple-
ment component 1 subcomponents; the herpes virus entry
mediator (Hvem), a member of the TNF receptor superfamily
and the ligand of the B and T lymphocyte attenuator (BTLA) [32];
Cxcl11, a T cell recruiting CXC chemokine (also known as
I-TAC); Toll-like receptor 1 (Tlr1); Clec4n, a C type lectin-like
receptor (also termed dectin-2). Among the transcripts with
decreased expression, the strongest differences were expectedly
found for genes not encoded in the genome of B6 mice, such as
Igh-1a (an allotype of the c2a gene encoding the heavy chain of
Table 1. Transcripts with increased expression in spleens of T. cruzi- infected susceptible B6 mice with respect to resistant F1 mice.
..................................................................................................................................................
Gene Symbol
a Gene Title (Annotations) Mean SLR
b Affymetrix Probe ID
Tcrb-V13/LOC384374/LOC436520 T-cell receptor beta, variable 13/similar to TCRBV3S1/similar to TCRBV3S1 3.7 1427849_a_at
Tcrb-V13/LOC384375/LOC386550 T-cell receptor beta, variable 13/similar to TCRBV7S1/similar to TCRBV7S1 3.2 1427752_a_at
1110033J19Rik RIKEN cDNA 1110033J19 gene (similar to ribosomal protein S4) 3.0 1452730_at
Adamdec1 ADAM-like, decysin 1 1.8 1419476_at
Mmp13 matrix metalloproteinase 13 1.7 1417256_at
Spp1/Opn secreted phosphoprotein 1 (osteopontin, Eta-1) 1.7 1449254_at
Marco macrophage receptor with collagenous structure 1.5 1449498_at
— Mus musculus, clone IMAGE:3983821, (mRNA, similar to ES derived homeobox) 1.2 1427820_at
Tspan4 tetraspanin 4 1.1 1448276_at
Snx6 sorting nexin 6 1.1 1451602_at
C1qb complement component 1, q subcomponent, beta polypeptide 1.0 1417063_at
2700079J08Rik Riken cDNA 2700079J08 gene/Gag protein (fragment) homolog 1.0 1436362_x_at
Erdr1 erythroid differentiation regulator 1 1.0 1452406_x_at
C1qb complement component 1, q subcomponent, beta polypeptide 1.0 1437726_x_at
C1qa complement component 1, q subcomponent, alpha polypeptide 1.0 1417381_at
Erdr1 Erythroid differentiation regulator 1 1.0 1439200_x_at
1700029I01Rik/LOC433791/LOC545705 RIKEN cDNA 1700029I01 gene/similar to RIKEN cDNA 1700029I01/similar to RIKEN
cDNA 1700029I01 (similar to zinc finger protein 665)
0.9 1424784_at
Klf9 Kruppel-like factor 9 0.9 1428288_at
Prdx2 peroxiredoxin 2 0.9 1430979_a_at
Tcrg T-cell receptor gamma chain, variable 4 0.9 1422188_s_at
Clec4n C-type lectin domain family 4, member n 0.9 1425951_a_at
C1qg complement component 1, q subcomponent, gamma polypeptide 0.9 1449401_at
Tlr1 toll-like receptor 1 0.9 1449049_at
Trim12 tripartite motif protein 12 0.9 1437432_a_at
Trim34/LOC434218 tripartite motif protein 34/similar to tripartite motif protein TRIM34 alpha 0.8 1424857_a_at
Wars tryptophanyl-tRNA synthetase 0.8 1415694_at
ifi203 interferon-activatable gene 203 0.8 1426906_at
Ndel1 nuclear distribution gene E-like homolog 1 (A. nidulans) 0.8 1424893_at
Affymetrix GeneChip Mouse Expression Array 430A
aBold gene title: Differential expression verified in an independent analysis, see text
bMean SLR: Signal log ratio, log2
doi:10.1371/journal.pone.0000057.t001
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e57Table 2. Transcripts with decreased expression in spleens of T. cruzi- infected susceptible B6 mice with respect to resistant F1 mice.
..................................................................................................................................................
Gene Symbol
a Gene Title (Annotations) Mean SLR
b Affymetrix Probe ID
Igh-1a immunoglobulin heavy chain 1a (serum IgG2a) 27.9 1451632_a_at
H2-Ea histocompatibility 2, class II antigen E alpha 27.9 1422892_s_at
H2-D1 histocompatibility 2, D region locus 1 27.6 1452544_x_at
H2-D1 histocompatibility 2, D region locus 1 27.4 1425614_x_at
Ifi202b interferon activated gene 202B 27.1 1421551_s_at
H2-Ea histocompatibility 2, class II antigen E alpha 26.2 1422891_at
H2-D1 histocompatibility 2, D region locus 1 26.2 1427651_x_at
Mela melanoma antigen 24.3 1456182_x_at
H2-Q1 Histocompatibility 2, D region locus 1 23.6 1451593_at
Mcpt2 mast cell protease 2 23.6 1449989_at
2210010A19Rik Riken cDNA 2210010A19 gene (hypoth. pyridoxal-dependent decarboxylase family
containing protein)
23.3 1419327_at
Ng23 Ng23 protein 23.1 1422952_at
Tnfrsf14/HVEM tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) 22.8 1452425_at
Gm288 Gene model 288, (NCBI) 22.8 1435998_at
Pnpt1 polyribonucleotide nucleotidyltransferase 1 22.5 1452677_at
Serpina1b/Serpina1d/Serpina1e serine (or cysteine) proteinase inhibitor, clade A, member 1b/serine (or cysteine)
proteinase inhibitor, clade A, member 1d/serine (or cysteine) proteinase inhibitor,
clade A, member 1e
22.4 1418282_x_at
Wdtc1 WD and tetratricopeptide repeats 1 22.2 1434560_at
Sfi1/LOC673420 Sfi1 homolog, spindle assembly associated (yeast)/similar to spindle assembly
associated Sfi1 homolog isoform b
22.1 1452195_s_at
Msh5 mutS homolog 5 (E. coli) 21.9 1430771_a_at
Gcg glucagon 21.7 1425952_a_at
LOC628926 hypothotetical protein LOC628926 21.7 1427553_at
Dnase1l3 deoxyribonuclease 1-like 3 21.6 1421056_at
Cxcl11 chemokine (C-X-C motif) ligand 11 21.6 1419697_at
Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) 21.5 1417461_at
Aps adaptor protein with pleckstrin homology and src 21.4 1450718_at
Bmp2k BMP2 inducible kinase 21.4 1421103_at
Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) 21.3 1417462_at
AI324046 expressed sequence AI324046 (immunoglobulin heavy chain, IgG3) 21.2 1447998_at
Foxj3 forkhead box J3 21.1 1438220_at
Ptp4a2 Protein tyrosine phosphatase 4a2 21.0 1435129_at
Ets1 E26 avian leukemia oncogene 1, 59 domain 21.0 1422028_a_at
D13Ertd608e DNA segment, chr 13, ERATO Doi 608, expressed 21.0 1439771_s_at
Srd5a2l steroid 5 alpha-reductase 2-like 21.0 1439241_x_at
Supt16h suppressor of Ty 16 homolog (S. cerevisiae) 21.0 1449578_at
E030041M21Rik RIKEN cDNA E030041M21 gene 20.9 1451276_at
37135 septin 1 20.9 1449898_at
Hyou1 hypoxia up-regulated 1 20.9 1423290_at
Rnf6 ring finger protein (C3H2C3 type) 6 20.8 1427899_at
Alad aminolevulinate, delta-, dehydratase 20.8 1424877_a_at
Tubb5 tubulin, beta 5 20.8 1455719_at
Rbm5 RNA binding motif protein 5 20.8 1456262_at
Comt catechol-O-methyltransferase 20.8 1418701_at
Affymetrix GeneChip Mouse Expression Array 430A
aBold gene title: Differential expression verified in an independent analysis, see text
bMean SLR: Signal log ratio, log2
doi:10.1371/journal.pone.0000057.t002
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PLoS ONE | www.plosone.org 6 December 2006 | Issue 1 | e57Ig2a immunoglobulins, [33]), H2-Ea (encoding H2-Ea, an MHC
class II protein) [34,35], and H2-D1 (encoding an MHC class Ia
protein not expressed in mice with the H2
b haplotype [36]).
Only a few differentially transcribed genes map to the suscepti-
bility loci on Chromosomes 5 and 17 (table 3). Three transcripts
map to the locus on Chromosome 5, with two (the IFN-inducible
chemokine Cxcl11, and Bmp2k, bone morphogenetic protein 2-
inducible kinase) being down-regulated, and one (Spp1) being
upregulated, in susceptible mice. Expression of Bmp2k and Spp1
transcripts were concordantly regulated in the second microarray
experiment. Cxcl11 mRNA was not detectable in either pool of
RNA in this experiment, but it was found to be about four-fold
decreased in infected B6 mice in an RT-PCR assay (O. Steinmetz,
personal communication), corroborating the results of the gene
array in which a signal log ratio of 21.6 was determined
(corresponding to a three-fold decrease, table 3). By contrast,
expression levels of two other CXC chemokines (Cxcl9 and Cxcl10)
did not vary between mice in either analysis.
Five transcripts that were significantly reduced in B6 mice map
to the locus on Chromosome 17, which covers the murine MHC
complex (table 3). All differences were confirmed in the second
microarray experiment with pooled RNA. One additional gene
(Glo1, glyoxalase 1) close to the locus on Chromosome 17 was
insignificantly (SLR20.6, equivalent to a 1.5 fold decrease) but
consistently regulated in that it was decreased in all 9 comparisons
between the 3 individual mice of either strain, and the regulation
was observed for several transcripts of the gene. It maps
centromerically to the suceptibility locus at about 16 cM.
No significant expression differences were found to map to the
putative locus on Chromosome 13 (cytogenetic band 13D2.3), but
three transcripts of an expressed gene (4833420G17Rik) were
reproducibly regulated below the threshold (SLR+0.4, eqivalent to
Table 3. T. cruzi susceptibility loci in B6 mice, and transcripts of genes encoded in these genomic regions that are differentially
expressed between T. cruzi- infected B6 and F1 mice.
..................................................................................................................................................
Chromosomal marker single-point
a multi-point
a differentially expressed transcripts
b
x
2 p-value x
2 p-value gene symbol mean SLR
b
Chromosome 5
d5mit20 15,52 4,08E-05 14,34 7,63E-05
d5mit155 14,78 6,04E-05 15,06 5,21E-05
d5mit157 16,00 3,17E-05 15,06 5,21E-05
d5mit10 18,65 7,85E-06 19,06 6,33E-06 Cxcl11 21.6
d5mit41 16,75 2,13E-05 18,28 9,53E-06 Bmp2k 21.4
d5mit403 17,52 1,42E-05 18,28 9,53E-06 Opn/Spp1/Eta-1 +1.7
d5mit239 16,25 2,78E-05 16,25 2,78E-05
d5mit240 16,00 3,17E-05 16,25 2,78E-05
d5mit25 18,06 1,07E-05 18,28 9,53E-06
Chromosome 13
d13mit148a 10,56 5,78E-04 9,62 9,65E-04
d13mit76a 12,55 1,98E-04 12,55 1,98E-04
d13mit230 12,25 2,33E-04 12,55 1,98E-04
d13mit262 10,90 4,81E-04 10,88 4,86E-04
d13mit151 6,00 7,15E-03 10,88 4,86E-04
d13mit77 11,95 2,73E-04 11,88 2,84E-04
MM13BM1 10,25 6,83E-04 13,64 1,11E-04
MM13BM2 12,94 1,61E-04 14,34 7,62E-05
d13mit35 13,64 1,11E-04 12,55 1,98E-04
Chromosome 17
d17mit173 20,08 3,71E-06 20,43 3,09E-06
d17mit30 20,43 3,09E-06 20,43 3,09E-06
d17mit198 19,64 4,67E-06 20,43 3,09E-06
d17mit135 22,70 9,47E-07 22,70 9,47E-07 H2-Ea 27.9
d17mit16 21,88 1,45E-06 22,70 9,47E-07 Msh5 21.9
d17mit234 21,06 2,23E-06 22,70 9,47E-07 Ng23 23.1
d17mit11 18,46 8,68E-06 22,70 9,47E-07 H2-D1 27.6
d17mit168 16,52 2,41E-05 20,43 3,09E-06 Tubb5 20.8
d17mit50 18,28 9,53E-06 18,28 9,53E-06
aSingle-point and multi-point calculations of x
2 for microsatellite markers typed in 68 susceptible B6xF1 backcross mice. x
2 and p values refer to a one-sided test for
homozygosity
bDifferentially expressed genes (derived from microarray analysis, see tables 1 and 2) in line with approximate genomic localisation; SLR, signal log ratio, log2.
Differential expression was confirmed by an independent analysis, see text
doi:10.1371/journal.pone.0000057.t003
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Chagas Susceptibility Genes
PLoS ONE | www.plosone.org 7 December 2006 | Issue 1 | e57a 1.3 fold increase). It encodes a protein with a gonadotropin beta
chain-like domain. The slightly increased expression in B6 mice
was confirmed in the pooled RNA microarray analysis. Another
transcript from this locus, Paip1 (polyadelynate binding protein-
interacting protein 1, a translation factor), was downregulated in 5
of 9 comparisons only (SLR21.9), but this could not be
substantiated in the second experiment.
Numerous gene transcripts have been shown to be involved in
immunity of Chagas’ disease and its experimental models. A few of
these displayed differential expression below the threshold level,
and there was concordant regulation in the microarray experiment
with pooled RNA samples. Several transcripts of inducible TGF-
b were increased in B6 mice (SLR+0.6). This is noteworthy as it
supports results of a previous investigation on the differences of the
immune response of B6 and F1 mice to T. cruzi in which increased
TGF-b expression was shown to enhance susceptibilty [28].
Transcription signals of CD44 (coding for an adhesion factor on
activated T and B cells; SLR+0.4), and of granzyme B (SLR+0.4)
were slightly upregulated in B6 mice. A downregulated transcrip-
tion signal in B6 mice was found for the beta chain of the IL-2
receptor (SLR20.5).
DISCUSSION
Disease following infection with a pathogen is the result of
a complex interaction between the host and the infectious agent
[37]. Both host and pathogen genomes are involved in de-
termining the severity of a sickness, and enviromental factors also
contribute to the course of an ailment. Genetic variation within
human cohorts complicates matters with respect to the identifi-
cation of genetic sources for disease severity, and in general,
several gene loci, splice variants and variation of gene copy
numbers are involved [38]. It is thus conceivable that the
identification of suceptibility genes to infectious diseases in man
has not been fruitful thus far, despite of the progress that genome
sequencing has achieved. Therefore, it may be a more straightfor-
ward approach to pinpoint genes that affect the severity of
infectious disease in animal models, and then to assess whether
orthologous mechanisms are at work in the human situation [39].
Since a hosts genotype manifests via transcription of genes,
candidate genes may be identified by a combination of mapping
data and transcriptional profiling. Determining the gene expres-
sion differences from susceptibility loci is thus a hypothesis-driven
experiment with the advantage that the multiple testing problem
of microarray analyses disappears and that the verification of the
gene expression data by independent methods is not strictly
required [40].
Morphological and cytometrical analysis of the organ with the
greatest differences in parasite loads, the spleen, revealed
a disruption of normal anatomical structure and modulation of
cellular composition in susceptible B6 mice. In addition, a sub-
stantial increase of apoptotic cells was observed, possibly
accounting further for the increased parasite burden, since the
presence of apoptotic cells were connected with increased parasite
proliferation, and with decreased trypanocidal activity of infected
macrophages [29]. B cell apoptosis has also been shown to
correlate with reduced numbers of B cells and with a suppressed
immune response to T. cruzi [41]. The loss of B cells and of splenic
follicles make a decreased humoral immune response to the
parasite a candidate pathogenetic pathway. Indeed, on day 17 of
infection, serologic reactivity to parasite antigens was decreased in
B6 mice for antibodies of all IgG subclasses, except for IgG2b,
when compared with F1 mice (unpublished observation). The
requirement of an effective humoral response for the resolution of
experimental T. cruzi infection has been demonstrated [42–44].
The bias towards macrophages at the expense of B cells in the
spleen of susceptible mice reproduces results of a previous study
with parasites of differential virulence. In this study, virulent
parasites, but not avirulent ones, caused a reduction of CD19+ B
cells, and an increase of Mac3+ macrophages, in the spleen of
infected mice [45].
We analysed genome wide expression in the spleen, prior to an
insufficient immune response to the parasite, and prior to the
profound alterations in cellular composition, in order to identify
transcriptional correlates of susceptibility that mapped to the
genomic susceptibility loci. We identified three candidate genes
from the susceptibility locus on Chromosome 5, and five from the
locus on Chromosome 17, with significantly different expression
between differentially resistant strains of mice. The organisation of
secondary lymphoid organs, such as the spleen, is regulated by
compartmentalised expression of lymphoid tissue chemokines,
enabling effective communication between lymphocytes and
antigen-presenting cells to mount protective immune responses
to pathogens. It was therefore interesting to find that the
expression of T cell attractant CXC chemokine ligand Cxcl11
mRNA was decreased in suscptible mice. CXCL11 is the most
potent agonist of the chemokine receptor CXCR3 that is
predominantly found on activated T cells, Th1 type T cells,
peripheral T cells and a subset of B cells [46,47]. It is produced by
monocytoid cells, epithelial cells, neutrophils and endothelial cells,
and its expression is induced by IFN-c. It is involved in generating
Th1 type immune responses. CXCL11 was also reported to be
a natural antagonist of CCR3 [48,49] and of CCR5 [47],
indicating a possible role in counteracting the effects of other
inflammatory chemokines such as RANTES, MIP-1a and MIP-
1b. More recently, CCR5 expression was shown to augment the
inflammatory reaction and to participate in host protection in
experimental Chagas’ disease [50,51]. It was now published that
CXCL11 also binds to a newly identified chemokine receptor,
CXCR7, that is expressed on activated endothelial and other cells,
providing a growth and survival advantage and adhesion
properties [52]. The role of CXCL11 in T. cruzi infection has
not been investigated, but the two other CXCR3- binding
chemokines, CXCL9 and CXCL10, were found to contribute to
a protective immune response in mice [53,54]. Decreased
expression of Cxcl11 mRNA in susceptible mice may be involved
in the insufficient immune response observed in B6 mice by
preventing adequate association between T cells and antigen-
presenting cells and/or B cells, or by reduced antagonism of
CCR3- and/or CCR5- mediated inflammatory reactions.
A further gene from the locus on Chromosome 5 with decreased
expression in B6 mice was Bmp2k. Bone morphogenetic proteins
play a role in skeletal development. Signalling involves transcrip-
tion of Bmp2k which encodes a serin/threonin kinase. Activation of
BMP2K attenuates osteocalcin expression and reduces osteoblast
differentiation [55]. Its role in infections in general, and its possible
role in determing the outcome of experimental T. cruzi infection,
remain to be determined.
Osteopontin (OPN; also termed secreted phosphoprotein 1,
SPP1, or early T lymphocyte activation 1, ETA-1) was primarily
described as an early adhesion receptor expressed after T cell
activation and mediating macrophage migration [56,57]. It is
regarded as an essential factor in inducing Th1 type immune
responses and has been described as a regulator of resistance to
microbial infection [58–61]. Recently, its role in Th1 type viral
immunity was disputed [62], and it was shown that SPP1 mediated
IFN-a production in plasmacytoid dendritic cells [63]. Several cells
express Spp1 following viral or bacterial infection, including
dendritic cells, T cells and macrophages, and it functions as
Chagas Susceptibility Genes
PLoS ONE | www.plosone.org 8 December 2006 | Issue 1 | e57a cytokine and anti-apoptotic growth factor, involved in adhesion,
chemotaxis, cell differentiation and inflammation. Osteopontin
was also found to participate in collagen fibrillogenesis and matrix
re-organisation in wound healing [64]. Transcription of Spp1 was
increased in T. cruzi susceptible B6 mice, indicating its role in
determining the strong Th1 type immune response. Possibly, its
expression is increased secondary to the severe disruption of
splenic architecture and due to an increased re-modelling activity.
Several genes within the susceptibility locus on Chromosome 17
were expressed at reduced levels in susceptible mice. The MHC
H2-D1 and H2-Ea genes are not encoded in B6 mice and signals
were thus drastically decreased. MHC encoded proteins are
essential for the presentation of antigens to T lymphocytes. MHC
polymorphism is believed to be driven by pathogen-based
mechanisms [65], and it has been associated with increased
resistance to a model infection [66]. The heterozygosity of the
intercross F1 at the MHC locus (H2
b/d) implies that a greater
number of antigens can potentially be presented to antigen-specific
T cells, resulting in a larger pool of lymphoytes that are able to
respond to the pathogen. Since a protective response to T. cruzi
infection requires both cellular and humoral acquired immune
effector mechanisms, it follows that both MHC class I and class II
genes are strong candidates for determining susceptibility.
However, the presence of a heterozygous state as such did not
necessarily confer resistance [14]. Certain H2 haplotypes were
associated with a protective effect under given experimental
conditions (reviewed by Campbell [3]). In the present study,
though, both parental strains succumbed to infection [15,30], and
neither H2 haplotype (neither H2
b nor H2
d) was thus protective in
itself. In man, the influence of HLA haplotypes on disease
progression has been demonstrated [6,67,68].
The other genes with decreased expression within the locus on
Chromosome 17 have not been assigned a role in immunity so far.
Tubb5 codes for the b5 isotype of the b-tubulin family and is
expressed at low levels ubiquitously [69]. Msh5 codes for a member
of the mismatch repair family of proteins, that is expressed mainly
in gonads and has a role in chromosome pairing during meiosis;
deficiency was associated with apoptosis of testicular and ovarian
cells and sterility [70,71]. The expressed sequence Ng23 has not yet
been classified regarding function or process [72].
The immunogenetic background of susceptibility of inbred mice
to experimental infections in general, and to experimental
infection with T. cruzi in particular, has not been delineated
despite progress in analysing numerous immunologic players and
pathways. The present work aimed at identifying candidates that
direct the many secondary variations of the immune response that
have been described. Further work is needed to substantiate these
proposals and to clarify the role of susceptibility genes in the
evolution of an ineffective immune response. It is important to
recognise that the results are strictly related to the common model
that has been used in this study. It is certainly probable that
alternate mechanisms apply in other inbred mice and with other
stocks and strains of T. cruzi.
MATERIALS AND METHODS
Parasites and mice
The T. cruzi tulahuen strain was used in all experiments. Mouse
experiments were registered at and approved by the Federal
Health Authorities of the State of Hamburg. Parasites were
maintained in Balb/c mice by fortnightly passage. Trypomasti-
gotes were counted in a Neubauer chamber following lysis in
a solution of NH4Cl (0.89% w/v) [73], and blood was
appropriately diluted with phosphate buffered saline (PBS) for
an experimental infection with 10
4 parasites. C57BL/6 (B6) and
C57BL/6xDBA/2 (B6D2F1, F1) mice were obtained from
Charles River (Sulzbach, Germany) and infected at the age of
6–8 weeks by inoculation of parasites into the peritoneum in
a volume of 200 ml. Parasitaemia was determined in 2 ml of tail
vein blood after lysis in 18 mlo fN H 4Cl.
Quantitative PCR
Relative tissue parasite burdens were determined by real time
PCR in specimens of about 20 mg of tissue. DNA extraction was
performed with a Gentra Puregene
TM tissue kit (Biozym, Hessisch
Oldendorf, Germany) according to the manufacturer’s instruc-
tions. DNA was dissolved in 50 mlo fH 2O, and a 100 fold dilution
was used for amplification. T. cruzi PCR was performed on an Abi
Prism 7700 SDS Instrument (Applied Biosystems, Weiterstadt,
Germany) as previously described [30]. The quantity of host DNA
was determined by real time PCR of b-actin from the same
samples as described [30], with the exception that thermal cycles
were 20 s at 95uC and 40 s at 58uC. The quantity of parasite DNA
in a given sample is expressed in relation to its content of b-actin
DNA.
Histology
Specimens from the spleen were obtained from naive and from
experimentally infected mice, fixed in buffered 10% formalin and
embedded in paraffin. Sections were stained with hematoxylin-
eosin (HE) and examined by light microscopy.
Immunohistochemistry
Spleen specimens were shock frozen in liquid nitrogen and stored
at 280uC until further processing. Sections of 5–8 mm were
stained with one of the following antibodies (obtained from
Beckton Dickinson, Heidelberg, Germany): anti-CD4; anti-CD8;
or anti-CD19; antibodies were diluted 1:50 in PBS. Sections were
then fixed in paraformaldehyde, and a secondary biotinylated anti-
rat Ig antibody was applied for 30 min. Detection was achieved
with streptavidin/horseradish peroxidase conjugate and developed
with the peroxidase substrate diaminobenzidine (Dako, Hamburg,
Germany). The TUNEL reaction on some sections was performed
with the ‘In Situ Cell Death Detection Kit, AP’ according to the
manufacturers instructions (Roche, Mannheim Germany) Sections
were counterstained with hematoxylin and analysed by optical
microscopy.
Flow cytometry
Spleen cell surface expression was analysed by staining of cell
suspensions with antibodies against either CD4 (Cy5-conjugated)
and CD8 (FITC-conjugated), against CD19 (PE-conjugated), or
against CD11b (PE-conjugated). Some samples were stained with
Annexin V and with propidium iodide to determine fractions of
apoptotic cells. All reagents were obtained from Becton Dickinson
(Heidelberg, Germany). Cells were fixed in 1% paraformaldehyde
and analysed with a FACSCalibur flow cytometer (Beckton
Dickinson, Mountain View, CA, USA) using the CellQuest
software. Results are expressed as the percentage of cells analysed
that were positive for the surface marker of interest.
Microsatellite genotyping
As an extension of our previous study [30], a further 22 male
backcross mice (B6xF1) were experimentally infected and
identified as being susceptible to a lethal outcome. Genomic
DNA of these animals was subjected to microsatellite genotyping
Chagas Susceptibility Genes
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17, 5, and 13, previously identified as putatively linked to
susceptibility. Nine polymorphic markers for each region were
analysed, as described elsewhere [30]. The markers MM13BM1
and MM13BM2 were identified on mouse Chromosome 13 and
amplified with the follwing primer pairs: MM13BM1F (59atagc-
caccaacaggcattg) and MM13BM1R (59FAM-tcggctttccctaaactgtg)
as well as MM13BM2F (59gcttaggcaatgggtctgatag) and
MM13BM2R (59HEX-tttgggtttgtatatgtctgactg). For statistical
analysis, genotyping data of the newly typed 22 animals were
combined with the original data set obtained from 46 susceptible
mice in the previous study. Chi-square statistics were computed
comparing the numbers of homozygous versus heterozygous mice.
The construction of the genetic maps was performed with
MAPMAKER/EXP v3.0b.
Microarray Analysis
Procedures for cDNA synthesis, labelling and hybridization were
carried out according to the manufacturer’s protocol (Affymetrix).
All experiments were performed using Affymetrix mouse genome
GeneChip 430A. Three mice of either strain (B6 and F1,
respectively) from three independent experiments were sacrificed
on day 11, the spleen was removed, and single cell suspensions
were prepared. All procedures were performed at 4uC. RNA was
prepared with a Qiagen RNeasy kit (Qiagen, Hilden, Germany)
according to the manufacturers instructions, and the quality of the
preparation was checked by agarose gel electrophoresis. In brief,
5 mg of total RNA were used for first strand cDNA synthesis with
an HPLC-purified T7-(dT)24 primer (One-Cycle cDNA Synthesis
Kit, Affymetrix). Synthesis of biotin-labeled cRNA was carried out
using the IVT Labeling Kit (Affymetrix) and then purified (Sample
Cleanup Module, Affymetrix). For hybridization, 15 mgo f
fragmented cRNA was incubated with the chip in 200 mlo f
hybridization solution in Hybridization Oven 640 (Affymetrix) at
45uC for 16 hours. GeneChips were then washed and stained
using the Affymetrix Fluidics Station according to the GeneChip
Expression Analysis Technical Manual. Microarrays were scanned
with the Agilent GeneArray Scanner, and the signals were
processed using the GeneChip expression analysis algorithm (v.2;
Affymetrix). To compare samples and experiments, the trimmed
mean signal of each array was scaled to a target intensity of 100.
Absolute and comparison analyses were performed with Affyme-
trix MAS (version 5.0, Affymetrix) software using default
parameters. To assist in the identification of genes that were
positively or negatively regulated in the experiment, we selected
genes that showed a signal log ratio of at least 0.8 (increase) or
20.8 (decrease) compared to the baseline (B6 compared to F1)
[74]. Annotations were further analyzed with interactive query
analysis at www.affymetrix.com. Pathways and other functional
groupings of genes were evaluated for differential regulation using
the visualisation tool GenMAPP (UCSF) as described elsewhere
[75,76].
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